Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Insulin Resistance But Without Diabetes
Phase of Trial: Phase II
Latest Information Update: 26 Apr 2017
Price : $35 *
At a glance
- Drugs Pegvisomant (Primary)
- Indications Insulin resistance
- Focus Therapeutic Use
- Acronyms PEGIR
- 12 May 2016 Status changed from active, no longer recruiting to completed.
- 16 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Jun 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.